OmniAb (OABI) Net Income towards Common Stockholders (2021 - 2026)
OmniAb's (OABI) quarterly Net Income towards Common Stockholders came in at -$7.7 million in Q1 2026, up 57.65% year-on-year from -$4.9 million in Q1 2025, and up 45.64% on a QoQ basis from -$14.2 million in Q4 2025.
OmniAb (OABI) Net Income towards Common Stockholders (2021 - 2026) Analysis & Trends
OmniAb (OABI) has 6 years of Net Income towards Common Stockholders data on file, last reported at -$7.7 million in Q1 2026.
- On a quarterly basis, Net Income towards Common Stockholders rose 57.65% year-over-year to -$7.7 million in Q1 2026; TTM through Mar 2026 was -$54.3 million, a 11.4% increase from a year earlier, with the FY2025 full-year figure at -$64.8 million, down 4.43% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$7.7 million, up from -$14.2 million in the prior quarter.
- Over the last five years, Net Income towards Common Stockholders for OABI reached as high as $6.8 million in Q4 2022 and fell as low as -$19.0 million in Q1 2024.
- Historically, Net Income towards Common Stockholders has averaged -$10.9 million across 5 years, with a median of -$14.1 million in 2023.
- On a YoY basis, Net Income towards Common Stockholders climbed as much as 7322.66% in 2022 and fell as far as 59393.5% in 2022.
- Year by year, Net Income towards Common Stockholders stood at $6.8 million in 2022, then sank by 306.06% to -$14.1 million in 2023, then climbed by 7.01% to -$13.1 million in 2024, then declined by 8.5% to -$14.2 million in 2025, then surged by 45.64% to -$7.7 million in 2026.
- Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$7.7 million in Q1 2026, -$14.2 million in Q4 2025, and -$16.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | -0.68 |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -453.82 Mn |
| 10 | OmniAb | 260.98 Mn | 211.91 Mn | 14.41 Mn | -7.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.71 Mn |
| Dec 31, 2025 | -14.18 Mn |
| Sep 30, 2025 | -16.53 Mn |
| Jun 30, 2025 | -15.88 Mn |
| Mar 31, 2025 | -18.20 Mn |
| Dec 31, 2024 | -13.07 Mn |
| Sep 30, 2024 | -16.37 Mn |
| Jun 30, 2024 | -13.63 Mn |
| Mar 31, 2024 | -18.96 Mn |
| Dec 31, 2023 | -14.05 Mn |
| Sep 30, 2023 | -15.74 Mn |
| Jun 30, 2023 | -14.73 Mn |
| Mar 31, 2023 | -6.10 Mn |
| Dec 31, 2022 | 6.82 Mn |
| Sep 30, 2022 | -1.97 Mn |
| Jun 30, 2022 | -1.30 Mn |
| Mar 31, 2022 | -3.67 Mn |
| Dec 31, 2021 | -94,425.00 |
| Sep 30, 2021 | -52,185.00 |
| Jun 30, 2021 | -2,185.00 |